January 1, 2022
There are many complex and highly regulated processes involved in bringing a drug to market. Oftentimes, departments within a pharmaceutical or biotech company don’t work together to communicate or share data. 7investing Lead Advisor Dana Abramovitz’s January 2022 recommendation is partnering with the life sciences industry to help them communicate better, share data, and make complex processes more efficient. This is helping to lower costs and speed time to market so they can get products to patients.
When you pick up a prescription at your pharmacy, do you ever think about the steps it took for that drug to get to you? It turns out there are many complex and highly regulated processes that take place to bring a drug to market and oftentimes the departments in a pharmaceutical or biotech company are disparate and don’t readily communicate or share information making it take even longer for that drug to get to you.
Hi. I’m Dana Abramovitz, 7investing Lead Advisor. We’re here to empower you to invest in your future by giving you our 7 best stock recommendations every month.
My recommendation this month is a technology company that is partnering with the life sciences industry to help them better communicate, share data, and make complex processes more efficient, lowering costs and speeding time to market. The company has great management, has been profitable for years, executes well, and is transforming the life sciences industry.
To learn more about all 7 stock recommendations this month, including mine, please visit 7investing.com/subscribe. We’re 7investing. We’re here to empower you to invest in your future.